CI - Cigna Corporation

NYSE - NYSE Delayed Price. Currency in USD
198.28
+0.41 (+0.21%)
At close: 4:03PM EST

198.25 -0.03 (-0.02%)
After hours: 4:19PM EST

Stock chart is not supported by your current browser
Previous Close197.87
Open197.74
Bid180.97 x 1000
Ask0.00 x 800
Day's Range196.04 - 199.13
52 Week Range163.02 - 226.61
Volume3,208,170
Avg. Volume2,936,581
Market Cap75.312B
Beta (3Y Monthly)0.97
PE Ratio (TTM)18.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.04 (0.02%)
Ex-Dividend Date2018-03-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Kemper (KMPR) Stock Rallies 38% in a Year's Time: Here's Why
    Zacks13 hours ago

    Kemper (KMPR) Stock Rallies 38% in a Year's Time: Here's Why

    Kemper's (KMPR) operational excellence should help the stock continue the bull run.

  • AIG Surges: Stock Moves 5.3% Higher
    Zacks14 hours ago

    AIG Surges: Stock Moves 5.3% Higher

    AIG saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Radian Group (RDN) Looks Good: Stock Adds 7.5% in Session
    Zacks14 hours ago

    Radian Group (RDN) Looks Good: Stock Adds 7.5% in Session

    Radian Group (RDN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Why Should You Hold on to Aon (AON) in Your Portfolio?
    Zacks2 days ago

    Why Should You Hold on to Aon (AON) in Your Portfolio?

    Banking high on a growing bottom line, strategic schemes and a robust financial standing, Aon (AON) promises to reap good returns for investors.

  • Jeff Auxier Establishes 4 New Holdings in 4th Quarter
    GuruFocus.com6 days ago

    Jeff Auxier Establishes 4 New Holdings in 4th Quarter

    Top buy is Daniel Loeb’s Cigna

  • Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
    Zacks8 days ago

    Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

    Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

  • InvestorPlace7 days ago

    UnitedHealth Stock Is a Buy, but Keep an Eye on the External Risks

    The case for insurer UnitedHealth Group (NYSE:UNH) seems almost too easy to make. UNH stock already has been one of the best performers in the market, rising 270% over the past five years. Earnings are expected to grow about 13% in 2019. Yet UnitedHealth stock trades at a seemingly attractive 18x multiple to this year's EPS guidance.With a 10% pullback from early December highs, a cheaper price seems to set up an attractive opportunity. UNH's recent performance and huge earnings growth speak well of management. The company's Optum unit is cutting-edge, and growing revenue while expanding margins. With $226 billion in revenue, meanwhile, UnitedHealth has the scale to serve customers and the size to pressure suppliers.All else equal, I'd expect UnitedHealth stock to keep climbing. Indeed, I recommended UNH a year ago, and even ~15% higher, I'm still bullish. But there are risks here, highlighted by near-term trading in UnitedHealth stock. And investors need to understand those risks before proceeding.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The Case for UnitedHealth StockThis simply seems like a good business. Growth has been phenomenal. The midpoint of 2019 EPS guidance of $14.40-$14.70 suggests a 155% increase from 2014 levels.Obviously, a lower tax rate and acquisitions have provided some outside help. But this is a company operating well, with revenue and margins both rising.UNH has a diversified portfolio, too. It has its hands in seemingly every market, with the insurer serving employers, individuals, Medicare, and state and local governments. The Global segment, built through targeted M&A, is now a $10 billion-plus revenue business.And Optum is at the forefront of changes in the industry. 2018 revenue rose double-digits, and operating margins continued to expand. Other PBMs (pharmacy benefit managers) are struggling. Rite Aid (NYSE:RAD) unit EnvisionRx has disappointed. Express Scripts managed to sell itself to Cigna (NYSE:CI), but at only a modest premium to 2015 highs. In that context, Optum's performance is even more impressive.This seems simply like a very attractive business. It's the largest health insurer in the world. Optum remains a roaring success. And yet UNH stock isn't that expensive, trading at less than 18x the midpoint of FY19 EPS guidance.Double-digit annual EPS growth, a 1.4% dividend and potentially a higher multiple over time mean UnitedHealth could return 10%+ annually for years to come. The Two Key Risks to UNH StockThere are two key risks, however. The first is that competitors are trying to gain scale themselves and expand their reach. Cigna bought out Express Scripts. CVS (NYSE:CVS) acquired Aetna. Rivals are coming after UnitedHealth's market lead.To be fair, larger mergers haven't played out. Cigna and Anthem (NYSE:ANTM) planned to merge back in 2017, but called it off. Aetna and Humana (NYSE:HUM) did the same. But competitors are trying to copy at least some of UnitedHealth's strategy, and their success could make them more formidable foes.The bigger risk is on the political front. UNH stock has struggled in recent sessions after the Trump Administration announced a plan to end drug rebates (which benefit PBMs like Optum). An apparently ham-handed response from Optum, which asked for 21 month's notice of any changes from drug manufacturers, brought some unwanted publicity, and framed Optum as potentially part of the problem - not the solution.From a long term standpoint, UnitedHealth almost certainly can adapt to any changes. But with net margins only just above 5%, even modest pressure on pricing, reimbursements, or other areas of the business can have a big impact on overall profits. And in the short-term, noise around regulatory changes could impact UnitedHealth stock, as appears to have been the case of late. A Matter of TrustAt these levels, at least some of the risks are priced in. And I'd be loath to put too much faith in the federal government, in particular, doing anything to notably change the healthcare model in the U.S.But that could change. A scenario where a Democratic candidate wins the Presidency in 2020 and is backed by a Democratic Congress is far from impossible. Should such a scenario seem plausible next year, UNH stock could start pricing in that risk.Right now, 18x earnings might seem cheap but it's not hard to picture UNH trading at 13-14x (or even worse) if investors believe regulators are coming for the company's margins.The changing political landscape and UnitedHealth's exposure to that landscape, mean this isn't a set-it-and-forget-it stock. Investors need to understand the risks and be willing to be nimble if political risk, in particular, starts to creep up.In the meantime, however, the pullback in UNH stock makes an attractive business available at an enviable price. And that's enough to make UNH a buy - at least for now.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post UnitedHealth Stock Is a Buy, but Keep an Eye on the External Risks appeared first on InvestorPlace.

  • Brandes Investments' Top 5 Buys in 4th Quarter
    GuruFocus.com7 days ago

    Brandes Investments' Top 5 Buys in 4th Quarter

    Top buys include Loeb’s new holding Cigna

  • Dan Loeb Increased Third Point’s Position in These Stocks in Q4
    Market Realist8 days ago

    Dan Loeb Increased Third Point’s Position in These Stocks in Q4

    Dan Loeb's Third Point Had a Weak 2018: Will 2019 Be Any Better?(Continued from Prior Part)Third Point’s only new position In Q4 2018, Third Point initiated a new position in Cigna (CI), which is an American healthcare services organization. Hike

  • Dan Loeb Buys Cigna and Sells Alibaba, Microsoft, Netflix
    GuruFocus.com8 days ago

    Dan Loeb Buys Cigna and Sells Alibaba, Microsoft, Netflix

    Third Point manager drops 10 positions in tough fourth quarter

  • Daniel Loeb's Third Point exits Alibaba, Microsoft, and Netflix
    Yahoo Finance9 days ago

    Daniel Loeb's Third Point exits Alibaba, Microsoft, and Netflix

    The hedge fund ditched some big tech names during the fourth quarter.

  • MarketWatch10 days ago

    Third Point drops stakes in Alibaba, Microsoft and Netflix in fourth quarter

    Dan Loeb's Third Point LLC sold stakes in several high profile companies including Alibaba Group Holdings , Microsoft Corp. , Netflix Inc. , and Deere & Co. while buying into Cigna Corp. during the fourth quarter, according to a regulatory filing Friday. It also dropped Marathon Petroleum Corp. and WPX Energy Inc. from its portfolio and trimmed its investment in American Express Co. to 2.9 million shares from 5 million in the previous quarter. At the same time, it raised its holding in Campbell Soup Co. to 21 million from 18 million as part of its effort to push for a sale of the company. For all of 2018, Third Point had reported losses of 11%, the worst since 2008. [Updated to correct that Third Point sold shares of Marathon Petroleum Corp. rather than Marathon Oil Corp.]

  • The World's Top 10 Health Care Companies (UNH, MDT)
    Investopedia11 days ago

    The World's Top 10 Health Care Companies (UNH, MDT)

    Discover the world's top 10 health care companies according to market capitalization, including a brief summary of each.

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Cigna Corp.

    Cigna Corp NYSE:CIView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CI. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CI totaled $18.11 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. CI credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Moody's12 days ago

    St. Paul Housing & Redevelopment Auth., MN -- Moody's affirms HealthPartners, Inc.'s (MN) A2; outlook stable

    Moody's Investors Service has affirmed HealthPartner, Inc.'s A2 revenue bond rating, affecting $488 million of rated debt (total debt outstanding, inclusive of unrated debt, is $723 million). The A2 rating reflects our expectation that HealthPartners (HP) will continue to benefit from a number of fundamental strengths, including its status as a fully integrated health system with diversified revenue streams, and its broad market reach throughout the Twin Cities area and broader Midwest region.

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of CI.N earnings conference call or presentation 1-Feb-19 1:30pm GMT

    Q4 2018 Cigna Corp Earnings Call

  • Top Ranked Value Stocks to Buy for February 5th
    Zacks14 days ago

    Top Ranked Value Stocks to Buy for February 5th

    Top Ranked Value Stocks to Buy for February 5th

  • Company News For Feb 4, 2019
    Zacks16 days ago

    Company News For Feb 4, 2019

    Companies in the news are: CI, HON, YUMC and CY

  • Barrons.com16 days ago

    Drug Pricing Risk Will Be With Cigna Stock for the Foreseeable Future

    The “catastrophically broken status quo” can’t continue, Health and Human Services secretary Alex Azar said. Now he is targeting pharmacy-benefit managers, and that’s not good news for the nation’s largest, Cigna.

  • The Wall Street Journal16 days ago

    [$$] Cigna’s $54 Billion Problem

    Cigna has more work to do if it wants to convince investors that its $54 billion deal was a good idea. The health insurer, which closed its acquisition of the pharmacy-benefits manager Express Scripts in December, unveiled its 2019 profit outlook Friday morning. Cigna expects adjusted earnings of $16 to $16.50 a share this year.

  • Lightning Strikes the Least Popular Middlemen in Healthcare
    Motley Fool18 days ago

    Lightning Strikes the Least Popular Middlemen in Healthcare

    The Trump administration's trying to throw a wrench into America's complex reimbursement system for expensive drugs.

  • The Wall Street Journal18 days ago

    [$$] Cigna Says Proposed Drug-Rebate Curbs Will Have Minimal Impact on Earnings

    Cigna Corp. said a new federal proposal that would curb rebates from drugmakers would have minimal impact on its results and offered conservative earnings guidance for 2019, the first year it will include the operations of Express Scripts Holding Co. Cigna said that for 2019, it projects adjusted income of $6.2 billion to $6.4 billion, or $16 to $16.50 per share. Analysts wrote that this range was slightly lower than consensus projections, but it included about $200 million, or 40 cents a share, in lingering overhead costs tied to Anthem Inc.’s early exit from its pharmacy-benefit contract with Express Scripts.

  • Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool18 days ago

    Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript

    CI earnings call for the period ending December 31, 2018.

  • TheStreet.com18 days ago

    Cigna Shares Fall Despite Strong Earnings

    Cigna reports quarterly earnings above forecasts but full-year guidance below analysts' expectations.